Alnylam Pharma (0HD2) Stock Statistics & Valuation Metrics

Alnylam Pharma has a market cap or net worth of $44.12B. The enterprise value is $43.74B.

Alnylam Pharma has 132,623,140 shares outstanding. The number of shares has decreased by -2.65% in one year.

Alnylam Pharma’s return on equity (ROE) is 0.40 and return on invested capital (ROIC) is 13.74%.

The current PE Ratio of Alnylam Pharma is 149.7. Alnylam Pharma’s PEG ratio is -0.79.

In the last 12 months, Alnylam Pharma had revenue of 3.71B and earned 313.75M in profits. Earnings per share was 2.39.

In the last 12 months, operating cash flow was 524.08M and capital expenditures -58.70M, giving a free cash flow of 465.38M billion.

Alnylam Pharma pays an annual dividend of $0.285, resulting in a dividend yield of ―

Alnylam Pharma upcoming earnings date is Apr 30, 2026, Before Open (Confirmed).

Alnylam Pharma as a current ratio of 2.76, with Debt / Equity ratio of 161.99%

In the past 12 months, Alnylam Pharma has paid 9.40M in taxes.

Alnylam Pharma EV to EBITDA ratio is 92.81, with an EV/FCF ratio of 111.12.

Alnylam Pharma has $2.91B in cash and marketable securities with $1.28B in debt, giving a net cash position of $1.63B billion.

Gross margin is 81.72%, with operating margin of 13.51%, and net profit margin of 8.45%.

The average price target for Alnylam Pharma is $455.84, which is 11.43% higher than the current price. The consensus rating is Strong Buy